Jazz earns expanded approval for drug with controversial history, prompting expert pushback
Twenty-seven years ago, the FDA and the National Organization for Rare Disorders approached executives of a small Minnesota drugmaker and asked whether they could turn a notorious date-rape drug and dangerous bodybuilder supplement into a treatment for narcolepsy.
Nearly three decades later that chemical, known as GHB, is a blockbuster medicine for Jazz Pharmaceuticals, generating nearly $2 billion per year in revenue. Now Jazz may have unlocked a way of vastly expanding the market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
